Fo­s­un Phar­ma con­sid­ers $3.8B sale of In­di­an drug­mak­er Gland Phar­ma — re­port

The Fo­s­un Phar­ma­ceu­ti­cal Group may be con­sid­er­ing the sale of a com­pa­ny it took a stake in just a few years ago.

Ac­cord­ing to a re­port from Bloomberg News on Tues­day, Fo­s­un is con­sid­er­ing the sale of the In­di­an-based in­jectable CD­MO Gland Phar­ma Ltd. af­ter it had re­port­ed­ly re­ceived in­ter­est from po­ten­tial buy­ers.

Bloomberg said in its re­port that Fo­s­un has been work­ing with an ad­vis­er as it in­for­mal­ly “gauges in­ter­est” in its con­trol­ling stake in Gland. Oth­er com­pa­nies and buy­out firms are in the be­gin­ning stages of look­ing at Gland, but no de­tails have emerged on any po­ten­tial buy­ers, the re­port says. The pub­li­ca­tion lists the mar­ket val­ue of Gland at around $3.8 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER